Kura Oncology Inc (KURA) : Birchview Capital Lp reduced its stake in Kura Oncology Inc by 25.28% during the most recent quarter end. The investment management company now holds a total of 59,114 shares of Kura Oncology Inc which is valued at $238,821 after selling 20,000 shares in Kura Oncology Inc , the firm said in a disclosure report filed with the SEC on Aug 9, 2016.Kura Oncology Inc makes up approximately 0.15% of Birchview Capital Lp’s portfolio.
Other Hedge Funds, Including , Mufg Americas Holdings Corp added KURA to its portfolio by purchasing 1,675 company shares during the most recent quarter which is valued at $8,777. Monashee Investment Management sold out all of its stake in KURA during the most recent quarter. The investment firm sold 175,000 shares of KURA which is valued $714,000. Minerva Advisors added KURA to its portfolio by purchasing 361,737 company shares during the most recent quarter which is valued at $1,486,016. Kura Oncology Inc makes up approx 0.97% of Minerva Advisors’s portfolio. Alethea Capital Management added KURA to its portfolio by purchasing 62,000 company shares during the most recent quarter which is valued at $267,840. Kura Oncology Inc makes up approx 0.36% of Alethea Capital Management’s portfolio.
Kura Oncology Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that target cell-signaling pathways certain cancers. It is developing its lead product candidate tipifarnib a farnesyl transferase inhibitor in both solid tumors and blood cancers with Harvey Rat Sarcoma Viral Oncogene Homolog (HRAS) mutations. Its tipifarnib has completed Phase I clinical trials. Its pipeline includes two preclinical programs. It is advancing KO-947 a small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2) as a potential treatment for patients with tumors. It is also developing orally available small molecule inhibitors of the menin-mixed lineage leukemia (menin-MLL) interaction which are in lead optimization as a treatment for patients with acute leukemias.